Eli Lilly says next-generation weight loss drug clears crucial obesity trial

Eli Lilly announced that its next-generation weight loss drug, retatrutide, has successfully cleared a pivotal late-stage Phase 3 trial in patients with obesity, demonstrating substantial and sustained weight loss across various doses. The highest dose of retatrutide led to an average weight loss of 28.3%, equivalent to 70.3 pounds, over 80 weeks, significantly outperforming the placebo group, which lost just 2.2%. Approximately 45% of the 2,500 trial participants achieved weight loss of 30% or more, marking a notable advancement in obesity treatment. The drug is administered as a weekly injection and operates through a different mechanism than existing therapies. In an extended study focusing on patients with a body mass index (BMI) of 35 or higher—who face elevated risks of cardiovascular disease and diabetes—the highest dose of retatrutide resulted in an average weight loss of 30.3% over 104 weeks. Despite some gastrointestinal side effects such as nausea and diarrhea, particularly at higher doses, these were consistent with previous trials and generally manageable. A lower dose of the drug was linked to fewer treatment discontinuations due to side effects. Lilly’s chief scientific officer, Dan Skovronsky, highlighted the significance of the 30% weight loss figure, noting it rivals results typically seen only with bariatric surgery. The trial’s outcomes position retatrutide as a potentially transformative option in obesity management, with about 65% of participants on the highest dose achieving a BMI below 30, the threshold for obesity classification. This performance surpasses Lilly’s existing weight loss drug Zepbound, which delivers around 20% to 22% weight reduction. Retatrutide has also demonstrated positive results in a diabetes trial and a smaller study involving patients with obesity and knee arthritis, reinforcing its broad therapeutic potential. Lilly is advancing retatrutide as a cornerstone of its obesity treatment portfolio, complementing its current injectable and oral options. The company plans to move forward with regulatory filings, aiming to bring this highly effective therapy to market and address the growing global obesity epidemic with a novel, potent alternative to surgery and existing medications.